Caribou Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Caribou Biosciences, Inc. (CRBU) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.34 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.41.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.64, a 28.17% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.84, a 76.40% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $0.40, a 88.20% decline from fiscal 2024.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.39, a 2.31% decline from fiscal 2023.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $3.47, a 61.40% increase from fiscal 2022.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $2.15, a 106.73% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.34 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $1.41 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $0.40 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $0.40 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.40 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $3.39 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $3.39 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $3.39 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $3.64 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $3.47 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $3.44 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $2.77 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $2.84 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $2.15 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $2.09 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $1.84 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $1.61 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $1.04 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $0.94 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $0.55 10-Q · filed 2021-09-02 | |||
| 2021-03-31 | $0.97 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |